Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro

International Journal of Pharmaceutics

Volumn 438, Issue 1-2, 2012, Pages 202-208

  Kalaria, Dhaval R ^a   Patel, Pratik ^b   Patravale, Vandana ^b   Kalia, Yogeshvar N ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Iontophoresis; MAO B inhibitors; Parkinson's disease; Transdermal drug delivery

Indexed keywords

CARBOMER; PARACETAMOL; RASAGILINE; SELEGILINE;

ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG PENETRATION; DRUG STABILITY; DRUG TRANSPORT; GEL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IONTOPHORESIS; NONHUMAN; PRIORITY JOURNAL; SKIN PERMEABILITY; STEADY STATE; SWINE; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ANIMALS; HUMANS; INDANS; IONTOPHORESIS; MONOAMINE OXIDASE INHIBITORS; SELEGILINE; SKIN; SWINE;

EID: 84867405642     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.08.037     Document Type: Article

References (21)

1. M.C. Anderson, and K.F. Tipton Estimation of monoamine-oxidase concentrations in soluble and membrane-bound preparations by inhibitor binding J. Neural Transm. Suppl. 41 1994 47 53
2. O. Bar Am, T. Amit, and M.B.H. Youdim Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline Neurosci. Lett. 355 2004 169 172
3. J.S. Barrett, S. Rohatagi, K. Dewitt, and R. Morales Bioequivalence of selegiline HCl: guidance for a "highly variable" drug Clin. Pharmacol. Ther. 59 1996 206
4. N.H. Bellantone, S. Rim, M.L. Francoeur, and B. Rasadi Enhanced percutaneous-absorption via iontophoresis. 1. Evaluation of an in vitro system and transport of model compounds Int. J. Pharm. 30 1986 63 72
5. J.A. Bodkin, and J.D. Amsterdam Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients Am. J. Psychiatry 159 2002 1869 1875
6. J.J. Chen, D.M. Swope, and K. Dashtipour Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease Clin. Ther. 29 2007 1825 1849
7. L.W. Elmer, and J.M. Bertoni The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy Expert Opin. Pharmacother. 9 2008 2759 2772
8. R.H. Howland Transdermal selegiline - a novel MAOI formulation for depression J. Psychosoc. Nurs. 44 2006 9 12
9. P. Jenner Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease Neurology 63 2004 S13 S22
10. Y.N. Kalia, A. Naik, J. Garrison, and R.H. Guy Iontophoretic drug delivery Adv. Drug Deliv. Rev. 56 2004 619 658
11. G.B. Kasting, and J.C. Keister Application of electrodiffusion theory for a homogeneous membrane to iontophoretic transport through skin J. Control. Release 8 1989 195 210
12. R. Levy, J.J. Thebault, and M. Guillaume The pharmacology of rasagiline: a potent, selective and irreversible MAO-B inhibitor: results from single- and multiple-dose phase I studies Movement Disord. 19 2004 S158 S159
13. P.A. LeWitt Mao-B inhibitor know-how: back to the pharm Neurology 72 2009 1352 1357
14. J.J. Mann, S.F. Aarons, P.J. Wilner, J.G. Keilp, J.A. Sweeney, T. Pearlstein, A.J. Frances, J.H. Kocsis, and R.P. Brown A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor Arch. Gen. Psychiatry 46 1989 45 50
15. M. Mawhinney, D. Cole, and A.J. Azzaro Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues J. Pharm. Pharmacol. 55 2003 27 34
16. V. Merino, A. Lopez, Y.N. Kalia, and R.H. Guy Electrorepulsion versus electroosmosis: effect of pH on the iontophoretic flux of 5-fluorouracil Pharm. Res. 16 1999 758 761
17. A.A. Patkar, C.U. Pae, and P.S. Masand Transdermal selegiline: the new generation of monoamine oxidase inhibitors CNS Spectr. 11 2006 363 375
18. C.U. Pae, H.K. Lim, C. Han, A. Neena, C. Lee, and A.A. Patkar Selegiline transdermal system: current awareness and promise Prog. Neuropsychopharmacol. Biol. Psychiatry 31 2007 1153 1163
19. J.A. Subramony, A. Sharma, and J.B. Phipps Microprocessor controlled transdermal drug delivery Int. J. Pharm. 317 2006 1 6
20. M. Steiger Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease Eur. J. Neurol. 15 2008 6 15
21. R. Tabakman, S. Lecht, and P. Lazarovici Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays 26 2004 80 90